Stereotaxis Continues Its Turnaround, Bringing Robots To Endovascular Intervention
Executive Summary
In an interview with Medtech Insight, Stereotaxis CEO David Fischel explained how the company intends to continue its recovery after a troubled near decade of decline.
You may also be interested in...
Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial
The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.
Tandem’s CSO Speaks On Insulin Pump Development And Its Challenges
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.
Off-The-Record At Jefferies London: Dealmaking In A Tumultuous Environment
The Jefferies London Healthcare Conference 2022 was packed with big medtech names, with Siemens Healthineers, Smith & Nephew and CMR Surgical among presenters. In-between seminars, Medtech Insight was able to glean some candid insights into medtech, pharma and finance that are rarely given freely.